Breaking News, Collaborations & Alliances

TFF Pharma, Catalent Enter Dry Powder Development and Manufacturing Agreement

Will focus on development of dry powder formulations of therapies, specifically biotherapeutics, for inhaled delivery.

Author Image

By: Charlie Sternberg

Associate Editor

TFF Pharmaceuticals Inc. and Catalent have entered a collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals’ patented Thin Film Freezing (TFF) technology.   Under the agreement, Catalent will provide its scale-up expertise and manufacturing capabilities to TFF Pharmaceuticals as its preferred development and manufacturing partner, and Catalent will be able to offer its c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters